Clinical Trial

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the safety, efficacy and cellular pharmacokinetics of GT801 injection in patients with moderate to severe refractory autoimmune diseases.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-03
Trial Details
NCT Number NCT07614191
Lead Sponsor Vivacta Biotechnology (Shanghai) Co., Ltd.
Collaborators: RenJi Hospital
Conditions Moderate to Severe Refractory Autoimmune Diseases
Enrollment 22 participants
Start Date 2026-05-25
Primary Completion 2031-12-30 (estimated)
Study Completion 2031-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-02